Keywords: UCB, Cimzia, US and EU regulatory filings, Psoriatic arthritis, Axial spondyloarthritis, Ph III

UCB files for US and EU approval for Cimzia for psoriatic arthritis and axial spondyloarthritis

Article | 20 February 2013

Print This

Belgium’s largest drugmaker, UCB (Euronext Brussels: UCB) says it has made two new regulatory filings with the US ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in